Bavarian Nordic has initiated a Phase II study evaluating Prostvac as a treatment for patients with metastatic castration-resistant prostate cancer.
The multicentre, randomised Phase II study will compare Prostvac followed by docetaxel (chemotherapy) versus docetaxel alone.
Go deeper with GlobalData
Patients in the Prostvac arm will receive an accelerated treatment with Prostvac followed by docetaxel and prednisone, while those in control arm will receive upfront docetaxel and prednisone.
The study is expected to enrol 144 patients by 2012.
The primary endpoint of the study is to assess the overall survival.
Secondary endpoints include evaluation of prostate-specific antigen (PSA) response rates, evaluation of the association between development of PSA-specific immune responses, time to progression and overall survival in patients treated with these regimens.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
